EmStop begins CAPTURE-2 trial of embolic protection system

EmStop has commenced the CAPTURE-2 IDE clinical trial, assessing its embolic protection system during TAVR procedures. The trial will examine the EmStop system’s safety and performance as a cerebral embolic protection device. TAVR is a minimally invasive procedure intended to replace an aortic valve that has difficulty in opening and closing properly. Credit: MAD.vertise / Shutterstock.com. EmStop has commenced the CAPTURE-2 investigational device exemption (IDE) clinical trial, assessing its embolic protection system during transcatheter aortic valve replacement (TAVR) procedures. The first participants in the CAPTURE-2 study received the treatment at Mission Hospital in Asheville, North Carolina, US. Combine business intelligence…

Source: Medical Device Network